Publications by authors named "M Bolos"
Purpose: Post hoc analysis of the JAVELIN Bladder 100 trial of avelumab maintenance in locally advanced/metastatic urothelial carcinoma (la/mUC) to determine the interaction by programmed death ligand 1 (PD-L1) status for overall survival (OS), and additional analyses of survival per a different PD-L1 expression cutoff of ≥ 1% in tumor cells or immune cells (TC/IC).
Methods: JAVELIN Bladder 100 data were used for the analysis of the interaction by PD-L1 status (per cutoff used in the trial) for OS and, additionally, OS and progression-free survival (PFS) analyses per a different ≥ 1% TC/IC PD-L1 expression cutoff (Ventana SP263 assay).
Results: No significant interaction between treatment and PD-L1 status was observed for OS.
Article Synopsis
- The study highlights the pressing challenges faced by manufacturing companies in waste management within a circular economy, focusing on the relationship between waste management information disclosure and financial performance.
- The findings indicate that although the average waste management disclosure score was initially low, it showed a significant improvement after 2019, positively correlating with return on assets.
- Additionally, factors like industry sensitivity to environmental issues, board size, and productivity were found to influence this relationship, while effects on liquidity measures like the current ratio were inconclusive.
Article Synopsis
- Management of advanced urothelial carcinoma has traditionally involved platinum-based chemotherapy, but most patients relapse quickly, leading to low survival rates before the advent of immunotherapy.
- New approaches, like first-line maintenance therapy with avelumab after initial chemotherapy response and the use of innovative drug classes, have significantly improved patient outcomes.
- The article provides a comprehensive review of current management strategies, recent advancements, and future developments in the treatment of advanced urothelial carcinoma, along with insights into the disease's biology.
Tauopathies are a group of neurodegenerative diseases characterized by the accumulation of hyperphosphorylated tau protein in the brain. Many of these pathologies also present an inflammatory component determined by the activation of microglia, the resident immune cells of the brain. p38 MAPK is one of the molecular pathways involved in neuroinflammation.
View Article and Find Full Text PDFAlzheimer's disease (AD) and other tauopathies are histopathologically characterized by tau aggregation, along with a chronic inflammatory response driven by microglia. Over the past few years, the role of microglia in AD has been studied mainly in relation to amyloid-β (Aβ) pathology. Consequently, there is a substantial knowledge gap concerning the molecular mechanisms involved in tau-mediated toxicity and neuroinflammation, thus hindering the development of therapeutic strategies.
View Article and Find Full Text PDF